Background: Interaction of the programmed death receptor 1 (PD1) and its ligand, PD-L1, has been
shown to suppress T cell activity and allows tumors to evade T cell mediated immune-response.
Our group recently showed that antigen-specific T cells transduced with a PD1-CD28
fusion receptor are protected from PD1-mediated inhibition. These cells are co-stimulated
via CD28 signalling, resulting in tumor-rejections in a murine model of pancreatic
cancer. The following study aims to proof the synergistic therapeutic effect of PD-1-CD28
fusion receptor transduced CD4+ and CD8+ T cells for immunotherapy of pancreatic cancer
and Non-Hodgkin-Lymphoma.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
A7
Identification
Copyright
© 2018 Published by Elsevier Inc.
